All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry

NVP-CGM097

CAS number:1313363-54-0    molecular formula:C38H47ClN4O4

overview

compound introduction

Information NVP-CGM097 NVP-CGM097 is a highly potent and selective MDM2 inhibitor with Ki value of 1.3 nM for hMDM2 in TR-FRET assay. It binds to the p53 binding-site of the Mdm2 protein, disrupting the interaction between both proteins, leading to an activation of the p53 pathway. Targets hMDM2 (Cell-free assay) 1.7 nM In vitro NVP-CGM097 binding to MDM2 is species dependent. It was shown to be selective for the p53:MDM2 interaction compared to the p53:MDM4 interaction (1176-fold selectivity) and the Ras:Raf interaction (3000-fold selectivity). In addition, NVP-CGM097 showed no significant activity against Bcl-2:Bak, Bcl-2:Bad, Mcl-1:Bak, Mcl-1:NOXA, XIAP:BIR3, and c-IAP:BIR3 protein-protein interactions. NVP-CGM097 was able to significantly redistribute wild-type p53 into the cell nucleus with an IC50 of 0.224 μM, demonstrating its ability to inhibit the p53:MDM2 interaction in living cells. NVP-CGM097 treatment leads to p53 nuclear translocation that results in cell growth inhibition in a p53-dependent manner. In vivo After iv administration, the total blood clearance (CL) of NVP-CGM097 was 5 mL/min/kg for mouse, 7 mL/min/kg for rat, 3 mL/min/kg for dog, and 4 mL/min/kg for monkey. On the basis of the respective hepatic blood flows, NVP-CGM097 showed a consistent low total blood CL in all species (5-10% of hepatic blood flow). The apparent terminal half-life (t1/2) was long in rodents and monkey (6-12 h) but was comparatively longer in dogs (20 h). After oral dosing, the compound was well absorbed with Tmax occurring between 1 and 4.5 h in all species tested. The oral bioavailability (%F) was high in mouse, rat, and dog and moderate in monkey. NVP-CGM097 was able to inhibit the interaction between p53 and MDM2 and reactivate the p53 pathway in vivo in a MDM2-amplified SJSA-1 human tumor model. p21 mRNA levels were found to increase concomitantly with levels of compound 1 in tumor-bearing rats dosed at 30 mg/kg. Daily treatment with NVP-CGM097 dose dependently and significantly inhibited SJSA-1 tumor growth in rats. Cell Research(from reference) Cell lines:Bon1 cells, NCI-H727 cells, Got1 cells Concentrations:0.1 nM-2500 nM Incubation Time:48 hrs, 96 hrs, 144 hrs or 216 hrs

Specs

Chinese alias-
English aliasAKOS030526402 | BP-10652 | NSC783015 | NSC-783015 | SCHEMBL2391196 | CCG-270337 | Uridine pyrophosphate a-delta-galactopyranosyl ester | BDBM162123 | CGM 097 [WHO-DD] | MFCD28144684 | (1S)-1-(4-chlorophenyl)-6-methoxy-2-[4-(methyl{[trans-4-(4-methyl-3-oxo
CAS number1313363-54-0molecular formulaC38H47ClN4O4
molecular weight659.26 g/molExact mass10mM in DMSO
PSA65.600 Ųlogp6.455

numbering system

No numbering system information yet

physicochemical properties

No physical and chemical property information yet

Safety information

No safety information yet

Production methods and uses

No production method and use information yet

Related

upstream information

No upstream information yet

downstream information

No downstream information yet

MSDS

Found 0 shareMSDS